Showing results (31-40 of 920) with videos related to
Sort By:
Pageof 92
Plos One|December 5, 2019
Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitisChristopher Scott, Rebecca Stokes, Kuan Minn Cha, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 11, 2023
Sex-differences in the association of interleukin-10 and interleukin-12 variants with the progression of hepatitis B virus infection in CaucasiansJanett Fischer, Eleni Koukoulioti, Tobias Müller, et al.Hepatobiliary Surgery and Nutrition|December 12, 2025
From NAFPD to MAFPD: a literature review of implications of a nomenclature changeWen Zheng, Wen-Yue Liu, Wenhui Lou, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 25, 2017
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling studySalvatore Petta, Mohammed Eslam, Luca Valenti, et al.Journal of Hepatology|November 11, 2017
Genetics and epigenetics of NAFLD and NASH: Clinical impactMohammed Eslam, Luca Valenti, Stefano RomeoNature Reviews. Gastroenterology & Hepatology|August 31, 2018
The changing epidemiology of liver diseases in the Asia-Pacific regionMartin C S Wong, Jason L W Huang, Jacob George, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 15, 2021
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approachTsubasa Tsutsumi, Mohammed Eslam, Takumi Kawaguchi, et al.Therapeutic Advances in Chronic Disease|May 19, 2025
Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort studyShadi Zerehpooshnesfchi, Fatema Safri, Ziyan Pan, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 18, 2022
Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitisShuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, et al.Current Opinion in Pharmacology|August 29, 2021
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunitiesZiyan Pan, Jian-Gao Fan, Mohammed EslamPageof 92